Peptilogics Closes $ 35.4 Million Series B Funding to Further Advance Proprietary Computational Peptide Drug Design and Discovery Platform
PITTSBURGH, December 21, 2020 / PRNewswire / – Peptilogics today announced the closing of a $ 35.4 million Series B financing. The financing was led by Presight Capital, with the participation of a new syndicate of investors comprising Founders Fund as well as existing investors. Pierre Thiel. Proceeds from the funding will be used to expand Peptilogics’ IT platform and invest in technologies to improve its drug design engine, as well as to accelerate the development of a peptide therapy pipeline, including the core clinical asset. from the Company, PLG0206, which demonstrated the first unmatched safety and efficacy.
“We are delighted to have the support of this union of visionary investors to accelerate our growth,” said Jonathan steckbeck, PhD, MBA, Founder and CEO of Peptilogics. “Our goal is to enable industry to unlock the full potential of peptides through the development of technologies that facilitate the rapid design of more effective treatments.”
Co-founder of Presight Capital Christian angermayer said, “We are building the world’s leading discovery and development platform for peptides because we believe that some of the most effective drugs in the world in the future will be peptides. “
Peptilogics combines proven drug development expertise with proprietary artificial intelligence (AI) and machine learning methods to solve challenges efficiently and accurately than the industry’s existing high-throughput screening-based discovery methods. have not been able to meet. Peptilogics’ computing platform finds connections between various biomedical data across the spectrum of drug development to map a new universe of peptide sequences. After learning the design language that governs peptide function, the platform then generates new, optimized therapies that align with a desired target drug profile and that are specifically designed to treat diseases from various indications.
“Peptilogics’ approach challenges traditional methods of drug discovery by starting with a defined target drug profile and working backwards to design optimal new molecules,” said Fabien Hansen of Presight Capital. “We believe that scalable rational design, not random screening, is the future of drug discovery and Peptilogics is well positioned to lead the way.”
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapies. Through its computing platform, Peptilogics radically alters drug discovery by not only uncovering new previously unexplored chemical design space, but ensuring that every potential therapy is biologically viable and scalable to manufacture. Peptilogics’ clinical-stage lead therapeutic peptide, PLG0206, is a novel broad-spectrum anti-infective that received orphan drug designation from the FDA and qualified product designation for infectious diseases for its original focus on the treatment of prosthetic joint infections, an unmet medical need. You can find more information about Peptilogics at www.peptilogics.com as well as on top Twitter and LinkedIn.
About Presight Capital
Presight Capital is the international entrepreneur and investor venture capital fund Christian angermayer. Presight takes a holistic approach to early stage investment opportunities in the advanced technology and biotechnology space. Presight is managed by two general partners Christian angermayer and Fabien Hansen, and their sponsors are – in addition to the Christian’s Family Office Apeiron as an anchor investor – mainly entrepreneurs and investors, who bring their respective networks and experience. Presight has been at the forefront of biotechnology investments and the originator of some of the most iconic recent life science companies including AbCellera, Compass Pathways, ATAI, Alloy, Rational Vaccines, Deciduous, EnClear, ChemomAb , Sensei and Angiex.
On Pierre Thiel
Pierre Thiel is the co-founder of PayPal and Palantir Technologies, as well as the first outside investor in Facebook. Thiel’s investment initiatives and entrepreneurial efforts span gender-defining companies in a variety of industries, including biotech companies such as Compass Pathways, ATAI and AbCellera.
About the Founders Fund
Founders Fund invests in the world’s largest and most valuable companies across all industries and all stages. The company’s partners have been the founders and early funders of companies such as PayPal, SpaceX, Palantir, Airbnb, Stripe, and Facebook. Founders Fund pursues a founders-friendly investment strategy, offering maximum support with minimum interference. More information is available at www.foundersfund.com.